{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:33:57Z","timestamp":1791722037564,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00987-z","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:57:05Z","timestamp":1783072625000},"page":"2723-2745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Polypharmacy, Potential Drug\u2013Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3800-5348","authenticated-orcid":false,"given":"Avinash M.","family":"Suntah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-3094","authenticated-orcid":false,"given":"Michael","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0864-181X","authenticated-orcid":false,"given":"Bassel","family":"Barhoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas E.","family":"Langenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Baldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Streckenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-774X","authenticated-orcid":false,"given":"Niklas","family":"Frahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-958X","authenticated-orcid":false,"given":"Felicita","family":"Heidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"10422","key":"987_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","volume":"403","author":"D Jakimovski","year":"2024","unstructured":"Jakimovski D, Bittner S, Zivadinov R, et al. Multiple sclerosis. Lancet. 2024;403(10422):183\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(23)01473-3.","journal-title":"Lancet"},{"issue":"14","key":"987_CR2","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler"},{"issue":"1","key":"987_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","volume":"10","author":"I Boutitah-Benyaich","year":"2025","unstructured":"Boutitah-Benyaich I, Eixarch H, Villacieros-\u00c1lvarez J, et al. Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Ther. 2025;10(1):324. https:\/\/doi.org\/10.1038\/s41392-025-02415-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"987_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","volume":"25","author":"MS Woo","year":"2024","unstructured":"Woo MS, Engler JB, Friese MA. The neuropathobiology of multiple sclerosis. Nat Rev Neurosci. 2024;25(7):493\u2013513. https:\/\/doi.org\/10.1038\/s41583-024-00823-z.","journal-title":"Nat Rev Neurosci"},{"issue":"44","key":"987_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100977","volume":"22","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024;22(44):100977. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100977.","journal-title":"Lancet Reg Health Eur"},{"issue":"10","key":"987_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4.","journal-title":"Lancet Neurol"},{"issue":"3","key":"987_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40120-025-00737-7","volume":"14","author":"M Levraut","year":"2025","unstructured":"Levraut M, Landes-Chateau C, Mondot L, Cohen M, Lebrun-Frenay C. The kappa free light chains index and central vein sign: two new biomarkers for multiple sclerosis diagnosis. Neurol Ther. 2025;14(3):711\u201331. https:\/\/doi.org\/10.1007\/s40120-025-00737-7.","journal-title":"Neurol Ther"},{"key":"987_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/978-3-031-60006-7_12","volume-title":"Neuroimmune diseases","author":"PS Rommer","year":"2024","unstructured":"Rommer PS, Hecker M, Zrzavy T, Zettl UK. General principles of immunotherapy in neurological diseases. In: Mitoma H, Manto M, editors. Neuroimmune diseases. Cham: Springer; 2024. p. 493\u2013535. https:\/\/doi.org\/10.1007\/978-3-031-60006-7_12."},{"issue":"7","key":"987_CR9","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016","volume":"12","author":"IA Samjoo","year":"2023","unstructured":"Samjoo IA, Drudge C, Walsh S, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023;12(7):e230016. https:\/\/doi.org\/10.57264\/cer-2023-0016.","journal-title":"J Comp Eff Res"},{"issue":"4","key":"987_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00415-025-13010-6","volume":"272","author":"AM Konitsioti","year":"2025","unstructured":"Konitsioti AM, Laurent S, Ellenberger D, et al. MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register. J Neurol. 2025;272(4):294. https:\/\/doi.org\/10.1007\/s00415-025-13010-6.","journal-title":"J Neurol"},{"issue":"14","key":"987_CR11","doi-asserted-by":"publisher","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","volume":"7","author":"G Macaron","year":"2023","unstructured":"Macaron G, Larochelle C, Arbour N, et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front Neurol. 2023;7(14):1197212. https:\/\/doi.org\/10.3389\/fneur.2023.1197212.","journal-title":"Front Neurol"},{"issue":"6","key":"987_CR12","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00415-024-12286-4","volume":"271","author":"Y Goereci","year":"2024","unstructured":"Goereci Y, Ellenberger D, Rommer P, et al. Persons with multiple sclerosis older than 55\u00a0years: an analysis from the German MS registry. J Neurol. 2024;271(6):3409\u201316. https:\/\/doi.org\/10.1007\/s00415-024-12286-4.","journal-title":"J Neurol"},{"issue":"12","key":"987_CR13","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1177\/1352458518799580","volume":"25","author":"PS Rommer","year":"2019","unstructured":"Rommer PS, Eichst\u00e4dt K, Ellenberger D, et al. Symptomatology and symptomatic treatment in multiple sclerosis: results from a nationwide MS registry. Mult Scler. 2019;25(12):1641\u201352. https:\/\/doi.org\/10.1177\/1352458518799580.","journal-title":"Mult Scler"},{"issue":"8","key":"987_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765\u201379. https:\/\/doi.org\/10.1001\/jama.2020.26858.","journal-title":"JAMA"},{"issue":"1","key":"987_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1365-2125.2000.00224.x","volume":"50","author":"HL Tremlett","year":"2000","unstructured":"Tremlett HL, Wiles CM, Luscombe DK. Nonprescription medicine use in a multiple sclerosis clinic population. Br J Clin Pharmacol. 2000;50(1):55\u201360. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00224.x.","journal-title":"Br J Clin Pharmacol"},{"key":"987_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ctim.2017.12.006","volume":"36","author":"M Gotta","year":"2018","unstructured":"Gotta M, Mayer CA, Huebner J. Use of complementary and alternative medicine in patients with multiple sclerosis in Germany. Complement Ther Med. 2018;36:113\u20137. https:\/\/doi.org\/10.1016\/j.ctim.2017.12.006.","journal-title":"Complement Ther Med"},{"issue":"9","key":"987_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11910-023-01289-9","volume":"23","author":"WD Chapman","year":"2023","unstructured":"Chapman WD, Herink MC, Cameron MH, Bourdette D. Polypharmacy in multiple sclerosis: prevalence, risks, and mitigation strategies. Curr Neurol Neurosci Rep. 2023;23(9):521\u20139. https:\/\/doi.org\/10.1007\/s11910-023-01289-9.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"987_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https:\/\/doi.org\/10.1186\/s12877-017-0621-2.","journal-title":"BMC Geriatr"},{"issue":"3","key":"987_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","volume":"12","author":"F Pazan","year":"2021","unstructured":"Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443\u201352. https:\/\/doi.org\/10.1007\/s41999-021-00479-3.","journal-title":"Eur Geriatr Med"},{"issue":"2","key":"987_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14740338.2020.1720646","volume":"19","author":"N Frahm","year":"2020","unstructured":"Frahm N, Hecker M, Zettl UK. Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert Opin Drug Saf. 2020;19(2):139\u201345. https:\/\/doi.org\/10.1080\/14740338.2020.1720646.","journal-title":"Expert Opin Drug Saf"},{"key":"987_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107011","volume":"107","author":"T Zhao","year":"2026","unstructured":"Zhao T, Ahmad H, Ng HS, et al. Polypharmacy prevalence, associated factors, and changes over time in Australians with multiple sclerosis. Mult Scler Relat Disord. 2026;107:107011. https:\/\/doi.org\/10.1016\/j.msard.2026.107011.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"987_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1177\/13524585241251986","volume":"30","author":"H Naizer","year":"2024","unstructured":"Naizer H, Wozny J, Krause TM, Huson E, Freeman L. Trends in central nervous system-active polypharmacy among people with multiple sclerosis. Mult Scler. 2024;30(9):1139\u201350. https:\/\/doi.org\/10.1177\/13524585241251986.","journal-title":"Mult Scler"},{"issue":"38","key":"987_CR23","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.2174\/1381612827666210728102832","volume":"27","author":"N Frahm","year":"2021","unstructured":"Frahm N, Hecker M, Zettl UK. Polypharmacy in chronic neurological diseases: multiple sclerosis, dementia and Parkinson\u2019s disease. Curr Pharm Des. 2021;27(38):4008\u201316. https:\/\/doi.org\/10.2174\/1381612827666210728102832.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"987_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/13524585221122207","volume":"29","author":"A Chertcoff","year":"2023","unstructured":"Chertcoff A, Ng HS, Zhu F, Zhao Y, Tremlett H. Polypharmacy and multiple sclerosis: a population-based study. Mult Scler. 2023;29(1):107\u201318. https:\/\/doi.org\/10.1177\/13524585221122207.","journal-title":"Mult Scler"},{"issue":"3","key":"987_CR25","first-page":"239","volume":"118","author":"J Thelen","year":"2021","unstructured":"Thelen J, Zvonarev V, Lam S, Burkhardt C, Lynch S, Bruce J. Polypharmacy in multiple sclerosis: current knowledge and future directions. Mo Med. 2021;118(3):239\u201345.","journal-title":"Mo Med"},{"issue":"6","key":"987_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/pds.4207","volume":"26","author":"C Evans","year":"2017","unstructured":"Evans C, Marrie RA, Zhu F, et al. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiol Drug Saf. 2017;26(6):702\u201311. https:\/\/doi.org\/10.1002\/pds.4207.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"14","key":"987_CR27","doi-asserted-by":"publisher","first-page":"1330066","DOI":"10.3389\/fneur.2023.1330066","volume":"21","author":"F Br\u00fcggemann","year":"2023","unstructured":"Br\u00fcggemann F, Gross S, S\u00fc\u00dfe M, et al. Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units. Front Neurol. 2023;21(14):1330066. https:\/\/doi.org\/10.3389\/fneur.2023.1330066.","journal-title":"Front Neurol"},{"key":"987_CR28","doi-asserted-by":"publisher","first-page":"106386","DOI":"10.1016\/j.msard.2025.106386","volume":"97","author":"C Atiyeh","year":"2025","unstructured":"Atiyeh C, Garjani A, Gilmartin C, et al. Medication use is associated with cognitive deficits in people with multiple sclerosis. Mult Scler Relat Disord. 2025;97:106386. https:\/\/doi.org\/10.1016\/j.msard.2025.106386.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"987_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1179\/1743132815Y.0000000036","volume":"37","author":"GA Jelinek","year":"2015","unstructured":"Jelinek GA, Weiland TJ, Hadgkiss EJ, Marck CH, Pereira N, van der Meer DM. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability. Neurol Res. 2015;37(8):662\u201373. https:\/\/doi.org\/10.1179\/1743132815Y.0000000036.","journal-title":"Neurol Res"},{"issue":"2","key":"987_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.53388\/DCT2022006","volume":"4","author":"RS de Mello","year":"2022","unstructured":"de Mello RS, Arnaud-Sampaio VF, Maciel LF, et al. Complex diseases demand novel treatment strategies: understanding drug combination. Drug Comb Ther. 2022;4(2):6. https:\/\/doi.org\/10.53388\/DCT2022006.","journal-title":"Drug Comb Ther"},{"issue":"3","key":"987_CR31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/pharmaceutics14030592","volume":"14","author":"P Bachmann","year":"2022","unstructured":"Bachmann P, Frahm N, Debus JL, et al. Prevalence and severity of potential drug\u2013drug interactions in patients with multiple sclerosis with and without polypharmacy. Pharmaceutics. 2022;14(3):592. https:\/\/doi.org\/10.3390\/pharmaceutics14030592.","journal-title":"Pharmaceutics"},{"issue":"13","key":"987_CR32","doi-asserted-by":"publisher","first-page":"204062232211083","DOI":"10.1177\/20406223221108391","volume":"4","author":"JL Debus","year":"2022","unstructured":"Debus JL, Bachmann P, Frahm N, et al. Associated factors of potential drug\u2013drug interactions and drug-food interactions in patients with multiple sclerosis. Ther Adv Chronic Dis. 2022;4(13):20406223221108390. https:\/\/doi.org\/10.1177\/20406223221108391.","journal-title":"Ther Adv Chronic Dis"},{"issue":"13","key":"987_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.946351","volume":"5","author":"M Hecker","year":"2022","unstructured":"Hecker M, Frahm N, Bachmann P, et al. Screening for severe drug\u2013drug interactions in patients with multiple sclerosis: a comparison of three drug interaction databases. Front Pharmacol. 2022;5(13):946351. https:\/\/doi.org\/10.3389\/fphar.2022.946351.","journal-title":"Front Pharmacol"},{"issue":"1","key":"987_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/pharmaceutics16010003","volume":"16","author":"M Hecker","year":"2023","unstructured":"Hecker M, Frahm N, Zettl UK. Update and application of a deep learning model for the prediction of interactions between drugs used by patients with multiple sclerosis. Pharmaceutics. 2023;16(1):3. https:\/\/doi.org\/10.3390\/pharmaceutics16010003.","journal-title":"Pharmaceutics"},{"issue":"5","key":"987_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.7224\/1537-2073.2021-139","volume":"25","author":"AB Ben-Zacharia","year":"2023","unstructured":"Ben-Zacharia AB, Walker B, Ross AP, et al. Factors associated with disease-modifying therapy adherence and persistence in multiple sclerosis: a scoping literature review. Int J MS Care. 2023;25(5):188\u201395. https:\/\/doi.org\/10.7224\/1537-2073.2021-139.","journal-title":"Int J MS Care"},{"key":"987_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","volume":"8","author":"C Evans","year":"2016","unstructured":"Evans C, Marrie RA, Zhu F, et al. Adherence and persistence to drug therapies for multiple sclerosis: a population-based study. Mult Scler Relat Disord. 2016;8:78\u201385. https:\/\/doi.org\/10.1016\/j.msard.2016.05.006.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"987_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043930","volume":"11","author":"C Evans","year":"2021","unstructured":"Evans C, Marrie RA, Yao S, et al. Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. BMJ Open. 2021;11(2):e043930. https:\/\/doi.org\/10.1136\/bmjopen-2020-043930.","journal-title":"BMJ Open"},{"issue":"5","key":"987_CR38","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s40120-025-00806-x","volume":"14","author":"E Smith","year":"2025","unstructured":"Smith E, Langdon D. Treatment adherence in MS: does objective MS knowledge and MS risk knowledge matter in relation to perceived disease-modifying therapy benefits? Neurol Ther. 2025;14(5):2107\u201323. https:\/\/doi.org\/10.1007\/s40120-025-00806-x.","journal-title":"Neurol Ther"},{"issue":"5","key":"987_CR39","doi-asserted-by":"publisher","first-page":"T230","DOI":"10.1016\/j.farma.2024.05.002","volume":"48","author":"MDMS Su\u00e1rez","year":"2024","unstructured":"Su\u00e1rez MDMS, Rold\u00e1n AM, Cuenca MRC, Morales AJ. Pharmaceutical recommendations for therapeutic appropriateness in patients with multiple sclerosis. Farm Hosp. 2024;48(5):T230\u20133. https:\/\/doi.org\/10.1016\/j.farma.2024.05.002.","journal-title":"Farm Hosp"},{"key":"987_CR40","doi-asserted-by":"crossref","unstructured":"Mashhadiakbar P, Hecker M, Frahm N, et al. Personality traits and their association with medication non-adherence in patients with multiple sclerosis. CNS Neurosci Ther. 2026 (submitted).","DOI":"10.1002\/cns.71020"},{"issue":"3","key":"987_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3111\/13696998.2012.667027","volume":"15","author":"JI Ivanova","year":"2012","unstructured":"Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601\u20139. https:\/\/doi.org\/10.3111\/13696998.2012.667027.","journal-title":"J Med Econ"},{"issue":"Suppl 6","key":"987_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00415-008-6016-8","volume":"255","author":"T Klauer","year":"2008","unstructured":"Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl 6):87\u201392. https:\/\/doi.org\/10.1007\/s00415-008-6016-8.","journal-title":"J Neurol"},{"issue":"8","key":"987_CR43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41582-025-01115-5","volume":"21","author":"A van der Walt","year":"2025","unstructured":"van der Walt A, Strijbis EMM, Bridge F, et al. Advancing multiple sclerosis management in older adults. Nat Rev Neurol. 2025;21(8):432\u201348. https:\/\/doi.org\/10.1038\/s41582-025-01115-5.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"987_CR44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"9","key":"987_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. https:\/\/doi.org\/10.1101\/cshperspect.a028928.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"987_CR46","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"issue":"D1","key":"987_CR47","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265\u201375. https:\/\/doi.org\/10.1093\/nar\/gkad976.","journal-title":"Nucleic Acids Res"},{"key":"987_CR48","unstructured":"DrugBank Online. Drug interaction checker. Edmonton (Canada): DrugBank (Wishart Research Group, University of Alberta); 2025. https:\/\/go.drugbank.com\/drug-interaction-checker. Accessed 2025 Oct 20."},{"issue":"1","key":"987_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57(1):289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"4","key":"987_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1467-9868.2010.00740.x","volume":"72","author":"N Meinshausen","year":"2010","unstructured":"Meinshausen N, B\u00fchlmann P. Stability selection. J R Stat Soc Ser B Stat Methodol. 2010;72(4):417\u201373. https:\/\/doi.org\/10.1111\/j.1467-9868.2010.00740.x.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"2","key":"987_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B Stat Methodol. 2005;67(2):301\u201320.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"#cr-split#-987_CR52.1","unstructured":"MS Registry of the German Multiple Sclerosis Society (DMSG). Update on the MS Registry of the German MS-Society, 2024 Edition. Hannover (Germany): MS Forschungs- und Projektentwicklungs-gGmbH"},{"key":"#cr-split#-987_CR52.2","unstructured":"2024. https:\/\/www.msregister.de\/fileadmin\/resources\/public\/documents\/publications\/brochure\/EN\/2024_Update_GMSR.pdf. Accessed 2026 Feb 26."},{"issue":"2","key":"987_CR53","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/brain\/awae245","volume":"148","author":"RP Holm","year":"2025","unstructured":"Holm RP, Wandall-Holm MF, Magyari M. Multiple sclerosis in Denmark (1950\u20132023): mean age, sex distribution, incidence and prevalence. Brain. 2025;148(2):626\u201334. https:\/\/doi.org\/10.1093\/brain\/awae245.","journal-title":"Brain"},{"issue":"8","key":"987_CR54","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10654-025-01276-z","volume":"40","author":"P Alping","year":"2025","unstructured":"Alping P, Frisell T, He A, Hillert J, Fink K, McKay KA. Completeness and generalizability of the Swedish MS register. Eur J Epidemiol. 2025;40(8):905\u201313. https:\/\/doi.org\/10.1007\/s10654-025-01276-z.","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"987_CR55","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fphar.2020.00418","volume":"5","author":"V Russo","year":"2020","unstructured":"Russo V, Orlando V, Monetti VM, et al. Geographical variation in medication prescriptions: a multiregional drug-utilization study. Front Pharmacol. 2020;5(11):418. https:\/\/doi.org\/10.3389\/fphar.2020.00418.","journal-title":"Front Pharmacol"},{"issue":"9","key":"987_CR56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s10654-024-01153-1","volume":"39","author":"S Yeamans","year":"2024","unstructured":"Yeamans S, Gil-de-Miguel \u00c1, Hern\u00e1ndez-Barrera V, Carrasco-Garrido P. Self-medication among general population in the European Union: prevalence and associated factors. Eur J Epidemiol. 2024;39(9):977\u201390. https:\/\/doi.org\/10.1007\/s10654-024-01153-1.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"987_CR57","doi-asserted-by":"publisher","first-page":"205521732093631","DOI":"10.1177\/2055217320936318","volume":"6","author":"K Pape","year":"2020","unstructured":"Pape K, Steffen F, Zipp F, Bittner S. Supplementary medication in multiple sclerosis: real-world experience and potential interference with neurofilament light chain measurement. Mult Scler J Exp Transl Clin. 2020;6(3):2055217320936318. https:\/\/doi.org\/10.1177\/2055217320936318.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"987_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107073","volume":"108","author":"G Feng","year":"2026","unstructured":"Feng G, Scandiffio J, Law V, Oh J, Bayley M, Simpson R. Prevalence and factors associated with polypharmacy among people with multiple sclerosis (PwMS) receiving outpatient rehabilitation: a cross-sectional study. Mult Scler Relat Disord. 2026;108:107073. https:\/\/doi.org\/10.1016\/j.msard.2026.107073.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"987_CR59","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1038\/s41598-019-40283-5","volume":"9","author":"N Frahm","year":"2019","unstructured":"Frahm N, Hecker M, Zettl UK. Multi-drug use among patients with multiple sclerosis: a cross-sectional study of associations to clinicodemographic factors. Sci Rep. 2019;9(1):3743. https:\/\/doi.org\/10.1038\/s41598-019-40283-5.","journal-title":"Sci Rep"},{"issue":"1","key":"987_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211120","volume":"14","author":"N Frahm","year":"2019","unstructured":"Frahm N, Hecker M, Zettl UK. Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: a single-center study. PLoS ONE. 2019;14(1):e0211120. https:\/\/doi.org\/10.1371\/journal.pone.0211120.","journal-title":"PLoS ONE"},{"issue":"1","key":"987_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/13524585221129964","volume":"29","author":"D Bourdette","year":"2023","unstructured":"Bourdette D, Herink M. Polypharmacy in multiple sclerosis: more is not necessarily better. Mult Scler. 2023;29(1):3\u20135. https:\/\/doi.org\/10.1177\/13524585221129964.","journal-title":"Mult Scler"},{"issue":"6","key":"987_CR62","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40264-024-01412-w","volume":"47","author":"L Li","year":"2024","unstructured":"Li L, Baker J, Quirk R, et al. Drug\u2013drug interactions and actual harm to hospitalized patients: a multicentre study examining the prevalence pre- and post-electronic medication system implementation. Drug Saf. 2024;47(6):557\u201369. https:\/\/doi.org\/10.1007\/s40264-024-01412-w.","journal-title":"Drug Saf"},{"issue":"290","key":"987_CR63","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3233\/SHTI220101","volume":"6","author":"L Villa Zapata","year":"2022","unstructured":"Villa Zapata L, Subbian V, Boyce RD, et al. Overriding drug\u2013drug interaction alerts in clinical decision support systems: a scoping review. Stud Health Technol Inform. 2022;6(290):380\u20134. https:\/\/doi.org\/10.3233\/SHTI220101.","journal-title":"Stud Health Technol Inform"},{"issue":"6","key":"987_CR64","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/jamia\/ocaa034","volume":"27","author":"H Edrees","year":"2020","unstructured":"Edrees H, Amato MG, Wong A, Seger DL, Bates DW. High-priority drug\u2013drug interaction clinical decision support overrides in a newly implemented commercial computerized provider order-entry system: override appropriateness and adverse drug events. J Am Med Inform Assoc. 2020;27(6):893\u2013900. https:\/\/doi.org\/10.1093\/jamia\/ocaa034.","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"987_CR65","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/0884533612467824","volume":"28","author":"K Robien","year":"2013","unstructured":"Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin\u00a0D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194\u2013208. https:\/\/doi.org\/10.1177\/0884533612467824.","journal-title":"Nutr Clin Pract"},{"issue":"2","key":"987_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/FTD.0000000000000924","volume":"44","author":"O Scherf-Clavel","year":"2022","unstructured":"Scherf-Clavel O. Drug\u2013drug interactions with over-the-counter medicines: mind the unprescribed. Ther Drug Monit. 2022;44(2):253\u201374. https:\/\/doi.org\/10.1097\/FTD.0000000000000924.","journal-title":"Ther Drug Monit"},{"key":"987_CR67","unstructured":"European Medicines Agency. Ocrevus (ocrelizumab): EPAR product information. Amsterdam (Netherlands): European Medicines Agency; 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf. Accessed 2026 Mar 20."},{"key":"987_CR68","doi-asserted-by":"publisher","unstructured":"Deeks ED. Cladribine tablets: a review in relapsing MS. CNS Drugs. 2018;32(8):785\u201396. https:\/\/doi.org\/10.1007\/s40263-018-0562-0.","DOI":"10.1007\/s40263-018-0562-0"},{"issue":"1","key":"987_CR69","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/13814788.2021.1917543","volume":"27","author":"E Rogero-Blanco","year":"2021","unstructured":"Rogero-Blanco E, Del-Cura-Gonz\u00e1lez I, Aza-Pascual-Salcedo M, et al. Drug interactions detected by a computer-assisted prescription system in primary care patients in Spain: MULTIPAP study. Eur J Gen Pract. 2021;27(1):90\u20136. https:\/\/doi.org\/10.1080\/13814788.2021.1917543.","journal-title":"Eur J Gen Pract"},{"issue":"11","key":"987_CR70","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40266-021-00898-8","volume":"38","author":"JE Hughes","year":"2021","unstructured":"Hughes JE, Russo V, Walsh C, Menditto E, Bennett K, Cahir C. Prevalence and factors associated with potential drug\u2013drug interactions in older community-dwelling adults: a prospective cohort study. Drugs Aging. 2021;38(11):1025\u201337. https:\/\/doi.org\/10.1007\/s40266-021-00898-8.","journal-title":"Drugs Aging"},{"key":"987_CR71","doi-asserted-by":"publisher","unstructured":"Kleiner D, Haghverdi F, Sz\u00e9pe O, et al. How to manage the overwhelming amount of database-detected interactions? A focus group meeting study on the management of database-detected risks of drug interactions. Eur J Hosp Pharm. 2026;33(3):213\u20138. https:\/\/doi.org\/10.1136\/ejhpharm-2025-004478.","DOI":"10.1136\/ejhpharm-2025-004478"},{"issue":"4","key":"987_CR72","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","volume":"269","author":"F Washington","year":"2022","unstructured":"Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022;269(4):1861\u201372. https:\/\/doi.org\/10.1007\/s00415-021-10850-w.","journal-title":"J Neurol"},{"issue":"4","key":"987_CR73","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jac5.1771","volume":"6","author":"KK Shah","year":"2023","unstructured":"Shah KK, Touchette DR, Marrs JC. Research and scholarly methods: measuring medication adherence. J Am Coll Clin Pharm. 2023;6(4):416\u201326. https:\/\/doi.org\/10.1002\/jac5.1771.","journal-title":"J Am Coll Clin Pharm"},{"issue":"7","key":"987_CR74","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s44411-025-00227-0","volume":"126","author":"P Schnorrerova","year":"2025","unstructured":"Schnorrerova P, Matalova P, Wawruch M. Medication adherence and intervention strategies: why should we care. Bratisl Med J. 2025;126(7):1196\u2013206. https:\/\/doi.org\/10.1007\/s44411-025-00227-0.","journal-title":"Bratisl Med J"},{"issue":"6","key":"987_CR75","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s10072-025-08055-4","volume":"46","author":"M Sefero\u011flu","year":"2025","unstructured":"Sefero\u011flu M, \u00c7\u0131nar BP, Tekan \u00dcY, et al. Treatment adherence in a large cohort of Turkish multiple sclerosis population. Neurol Sci. 2025;46(6):2737\u201346. https:\/\/doi.org\/10.1007\/s10072-025-08055-4.","journal-title":"Neurol Sci"},{"issue":"4","key":"987_CR76","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/1352458516657440","volume":"23","author":"KA McKay","year":"2017","unstructured":"McKay KA, Tremlett H, Patten SB, et al. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study. Mult Scler. 2017;23(4):588\u201396. https:\/\/doi.org\/10.1177\/1352458516657440.","journal-title":"Mult Scler"},{"issue":"4","key":"987_CR77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fphar.2013.00091","volume":"25","author":"P Kardas","year":"2013","unstructured":"Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;25(4):91. https:\/\/doi.org\/10.3389\/fphar.2013.00091.","journal-title":"Front Pharmacol"},{"issue":"18","key":"987_CR78","doi-asserted-by":"publisher","first-page":"212","DOI":"10.7812\/TPP\/18.212","volume":"24","author":"EA Lee","year":"2020","unstructured":"Lee EA, Brettler JW, Kanter MH, et al. Refining the definition of polypharmacy and its link to disability in older adults: conceptualizing necessary polypharmacy, unnecessary polypharmacy, and polypharmacy of unclear benefit. Perm J. 2020;24(18):212. https:\/\/doi.org\/10.7812\/TPP\/18.212.","journal-title":"Perm J"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00987-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00987-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00987-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:37Z","timestamp":1790381017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00987-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00987-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Hecker received speaking fees and travel funds from Bayer HealthCare, Biogen, Merck Healthcare, Novartis, and Teva. Niklas Frahm received travel funds for research meetings from Novartis. Felicita Heidler received speaking fees and travel funds from Bayer HealthCare, Biogen, Bristol Myers Squibb, Janssen, Merck Healthcare, Neuraxpharm, Novartis, Roche, Sanofi Genzyme, and Teva. Uwe K. Zettl received research support, speaking fees, and travel funds from Alexion, Almirall, Bayer HealthCare, Biogen, Bristol Myers Squibb, Janssen, Merck Healthcare, Novartis, Roche, Sanofi Genzyme, and Teva as well as the European Union, BMBF, BMWi, and DFG. Avinash M. Suntah, Bassel Barhoum, Jonas E. Langenberger, Julia Baldt, Barbara Streckenbach, and J\u00f6rg Richter declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the ethics committee of the University of Rostock (permit number A 2019-0048) and the Medical Chamber of Thuringia (reference number 23117\/2019\/88). The study was conducted in accordance with the Declaration of Helsinki and the European General Data Protection Regulation. All participants provided written informed consent prior to inclusion.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}